Zymeworks Inc (ZYME) is now in the Overvalued zone, suggesting that its current forward PS ratio of 20.84 is considered Overvalued compared with the five-year average of -3.83. The fair price of Zymeworks Inc (ZYME) is between 8.52 to 16.58 according to relative valuation method. Compared to the current price of 23.05 USD , Zymeworks Inc By Overvalued By 39.05%.

Relative Value

Fair Zone

8.52-16.58

Current Price：23.05

39.05%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Zymeworks Inc (ZYME) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Zymeworks Inc (ZYME) has a current Price-to-Book (P/B) ratio of 6.25. Compared to its 3-year average P/B ratio of 2.22, the current P/B ratio is approximately 181.78% higher. Relative to its 5-year average P/B ratio of 2.40, the current P/B ratio is about 160.58% higher. Zymeworks Inc (ZYME) has a Forward Free Cash Flow (FCF) yield of approximately -3.29%. Compared to its 3-year average FCF yield of 2.24%, the current FCF yield is approximately -246.63% lower. Relative to its 5-year average FCF yield of -12.33%, the current FCF yield is about -73.34% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ZYME competitors is 10.61, providing a benchmark for relative valuation. Zymeworks Inc Corp (ZYME.O) exhibits a P/S ratio of 20.84, which is 96.41% above the industry average. Given its robust revenue growth of 72.59%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ZYME increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ZYME in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ZYME currently overvalued or undervalued?

What is Zymeworks Inc (ZYME) fair value?

ZYME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Zymeworks Inc (ZYME) is between 8.52 to 16.58 according to relative valuation method.

How does ZYME's valuation metrics compare to the industry average?

The average P/S ratio for ZYME's competitors is 10.61, providing a benchmark for relative valuation. Zymeworks Inc Corp (ZYME) exhibits a P/S ratio of 20.84, which is 96.41% above the industry average. Given its robust revenue growth of 72.59%, this premium appears sustainable.

What is the current P/B ratio for Zymeworks Inc (ZYME) as of Mar 02 2026?

As of Mar 02 2026, Zymeworks Inc (ZYME) has a P/B ratio of 6.25. This indicates that the market values ZYME at 6.25 times its book value.

What is the current FCF Yield for Zymeworks Inc (ZYME) as of Mar 02 2026?

As of Mar 02 2026, Zymeworks Inc (ZYME) has a FCF Yield of -3.29%. This means that for every dollar of Zymeworks Inc's market capitalization, the company generates -3.29 cents in free cash flow.

What is the current Forward P/E ratio for Zymeworks Inc (ZYME) as of Mar 02 2026?

As of Mar 02 2026, Zymeworks Inc (ZYME) has a Forward P/E ratio of -28.70. This means the market is willing to pay $-28.70 for every dollar of Zymeworks Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zymeworks Inc (ZYME) as of Mar 02 2026?

As of Mar 02 2026, Zymeworks Inc (ZYME) has a Forward P/S ratio of 20.84. This means the market is valuing ZYME at $20.84 for every dollar of expected revenue over the next 12 months.

ZYME Valuation